Anifrolumab-fnia, an IFNAR1-blocking monoclonal antibody, is now authorized for weekly subcutaneous self-administration in ...
The new weekly 120mg SC formulation, supported by TULIP-SC trial results, offers patients with moderate to severe SLE a self-administered alternative to monthly IV infusions.
AstraZeneca’s SAPHNELO ® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen , for the treatment of adult patients with systemic ...
In a new analysis of Phase 2 and 3 anifrolumab (Saphnelo®) clinical trial data, researchers found that the SLE Disease ...
The U.S. Food and Drug Administration (FDA) has accepted Genentech’s supplemental Biologics License Application for Gazyva® ...
Objectives To assess indirect costs (IDC) due to lost productivity in paid/unpaid labour, stratified by sex, in a national ...
Women with systemic lupus erythematosus who receive immunosuppressive therapy show a higher prevalence of cervical lesions and cervical human papillomavirus infection than immunocompetent women.
Objective The multinational ERYTHRO ( NCT06046534) study investigated the experience of patients with moderate-to-severe SLE ...
SSc and SLE are chronic autoimmune diseases with distinct and overlapping characteristics, including fibrosis in SSc and systemic inflammation in SLE. RNA sequencing identified differentially ...
When people talk about “lupus,” they usually mean systemic lupus erythematosus (SLE), the most common type. But there are several other types and subtypes, some of which can overlap. Lupus is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results